ClinicalTrials.Veeva

Menu
C

Clinical Research of Osceola | Kissimmee, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SAR441566
RO7790121
BI 3032950

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 5 total trials

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-1)

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) co...

Enrolling
Moderately to Severely Active Ulcerative Colitis
Drug: Afimkibart
Drug: Placebo

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance...

Enrolling
Moderately to Severely Active Crohns Disease
Drug: Placebo
Drug: Afimkibart

This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety o...

Enrolling
Crohn's Disease
Drug: SAR441566
Drug: SAR441566 matching Placebo

This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety o...

Enrolling
Colitis Ulcerative
Drug: SAR441566 matching Placebo
Drug: SAR441566

Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment w...

Enrolling
Ulcerative Colitis
Drug: BI 3032950 intravenous (Part A)
Drug: BI 3032950 subcutaneous (Part B)

Trial sponsors

Roche logo
Sanofi logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems